A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Sponsor: Eli Lilly and Company

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT07218341

Patient View

This study assesses the long-term safety of pirtobrutinib in participants with CLL/SLL who completed the J2N-MC-JZNN/LOXO-BTK-20020 trial. Eligible participants will receive oral pirtobrutinib or idelalisib every 4 weeks. The trial aims to provide continued access to treatment and follow-up over approximately 5 years.

Patient Parameters

Program Overview

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Eligibility Criteria

Inclusion Criteria

  • Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria

  • This is not applicable to this study

Get This Program In Your Inbox

You can sign up and apply your patients for this program.